NCT05582161

Efficacy Biomarkers of DAOIB for Dementia

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 123 (estimated)
• Sponsor: Chang Gung Memorial Hospital · Academic / Other
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress - related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.

Conditions

• Dementia

Interventions

Type	Name	Description
DRUG	DAOIB	The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.

Timeline

• Start date: 2022-10-03
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2022-10-17
• Last updated: 2026-03-19

Locations

2 sites across 1 country: Taiwan